Bristol-Myers Squibb Co (NYSE:BMY) Position Boosted by Cobblestone Capital Advisors LLC NY

Cobblestone Capital Advisors LLC NY lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 8.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 18,953 shares of the biopharmaceutical company’s stock after purchasing an additional 1,517 shares during the quarter. Cobblestone Capital Advisors LLC NY’s holdings in Bristol-Myers Squibb were worth $904,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc raised its position in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after purchasing an additional 1,229,553 shares during the last quarter. BlackRock Inc. raised its position in shares of Bristol-Myers Squibb by 0.9% in the 4th quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after acquiring an additional 999,193 shares in the last quarter. Northern Trust Corp raised its position in shares of Bristol-Myers Squibb by 4.4% in the 4th quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after acquiring an additional 954,877 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Bristol-Myers Squibb by 1.1% in the 4th quarter. Bank of New York Mellon Corp now owns 17,303,884 shares of the biopharmaceutical company’s stock worth $899,456,000 after acquiring an additional 180,711 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $797,038,000. Institutional investors and hedge funds own 77.65% of the company’s stock.

In related news, insider Karen Murphy Santiago sold 3,065 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the transaction, the insider now directly owns 3,066 shares in the company, valued at $145,818.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was bought at an average price of $47.29 per share, with a total value of $236,450.00. Following the completion of the transaction, the director now directly owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The disclosure for this purchase can be found here. Insiders own 0.12% of the company’s stock.

BMY has been the subject of several research analyst reports. Credit Suisse Group reissued a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. BMO Capital Markets reissued a “buy” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, February 19th. Bank of America lowered their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, February 22nd. Finally, ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $56.69.

BMY stock opened at $46.87 on Wednesday. The stock has a market cap of $76.47 billion, a price-to-earnings ratio of 11.78, a P/E/G ratio of 2.19 and a beta of 0.74. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. Bristol-Myers Squibb Co has a 52-week low of $44.30 and a 52-week high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.01. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The business had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the previous year, the business earned $0.94 EPS. The company’s quarterly revenue was up 14.0% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Co (NYSE:BMY) Position Boosted by Cobblestone Capital Advisors LLC NY” was first published by Modern Readers and is the sole property of of Modern Readers. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.modernreaders.com/news/2019/06/12/bristol-myers-squibb-co-nysebmy-position-boosted-by-cobblestone-capital-advisors-llc-ny.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: Forex

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.